Navigation Links
Treatment for Cigarette, Alcohol & Drug Use During Pregnancy Dramatically Improves Outcomes for Mom and Baby, Kaiser Permanente Study Shows
Date:6/26/2008

Largest study to date examined nearly 50,000 pregnant women

OAKLAND, Calif., June 26 /PRNewswire/ -- Pregnant women who receive treatment for substance abuse early in their pregnancy can achieve the same health outcomes as pregnant women with no substance abuse, according to a Kaiser Permanente study published online in the Journal of Perinatology.

The study, which is the largest to date, examined 49,985 women in Kaiser Permanente's prenatal care program and found that integrating substance abuse screening and treatment into routine prenatal care helped pregnant women achieve similar health outcomes as women who were not using cigarettes, alcohol or other drugs. This is also the largest study to examine multiple substances: cigarettes, alcohol, marijuana, methamphetamines, cocaine and heroin.

"This program can happen everywhere and should become the gold standard for women who are pregnant and using cigarettes, alcohol or other drugs," said study lead author Nancy C. Goler, M.D., an OB/GYN and Kaiser Permanente regional medical director of the Early Start Program for the organization's Northern California operations. "The study's big finding was that study participants treated in the Early Start program had outcomes similar to our control group, women who had no evidence of substance abuse."

The study compared 2,073 pregnant women who were screened, assessed and received ongoing intervention during pregnancy through the Early Start program at 21 Kaiser Permanente Northern California outpatient obstetric clinics from 1999 to 2003 to women in three other groups: 156 women who were screened but did not accept assessment or treatment; 1,203 women were screened, assessed and received brief intervention only; and a control group of 46,553 women who showed no evidence of substance abuse.

The study found the risk of stillborn, placental abruption (when the placental lining separates from the mother's uterus), pre-term delivery,
'/>"/>

SOURCE Kaiser Permanente
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Rheumatoid Arthritis Treatment Guidelines Updated
2. Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy
3. Adoption of Minimally Invasive Prostate Cancer Treatment Options Slow
4. Leading Eating Disorder Treatment Center Identifies Popular Diet Myths
5. California Drug Rehab Program Launches New Life Skills Classes to Young Adults as Substance Abuse Treatment
6. State policies influence drug treatment programs
7. National Headache Foundation Offers Statement, Experts on Appropriate Use of Medications for Migraine Treatment
8. Medical Pot Ineffective as Acute Pain Treatment
9. Younger Patients Seeking More Aesthetic Treatments
10. Prescribed Meds Still Best Treatment for Alcoholism
11. Revolutionary Therapy: Needle-Free Technology for the Treatment Of Blinding Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 As AndroGel lawsuits and testosterone ... E. Johnson, Jr. has been appointed as co-lead counsel ... testosterone medications. Since the Fall of 2013, Ron and ... diligently to investigate and prosecute the claims of men ... clots as a result of taking testosterone. As a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
(Date:8/1/2014)... August 01, 2014 The "Antimicrobial ... such as Zinc Oxide, Titanium Dioxide, and Zinc ... & Construction, Food & Beverages, Textiles, and others), ... - Global Trends and Forecasts to 2018" analyzes ... drivers, opportunities, and trends in the diverse geographical ...
(Date:8/1/2014)... 2014 According to new market ... (Asia-Pacific, North America, Europe, & ROW), by Vehicle ... Type (Gasoline & Diesel), by After-Treatment Device (DPF, ... & Forecasts to 2019", defines and segments the ... of major countries in all the regions, and ...
(Date:8/1/2014)... NY August 1, 2014 The Cardiovascular ... and first report investigations that will be presented ... scientific symposium. TCT, the world,s premier educational meeting ... September 13 17, 2014 at the Walter ... Clinical research data presented at TCT often direct ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... Nov. 28 GAB Robins is pleased to,announce that ... Adjusting,Sales for North American Operations. In this position, Ms. ... and will be responsible for,increasing business development opportunities for ... been with GAB Robins for seven years. Most recently, ...
... Nov. 28 In recognition of,National ... Inc., (http://www.HealthCentral.com ) today has launched ... informs online users about acne,aging skin, ... reliable medical information and a,community forum ...
... N.J., Nov. 28 RadPharm, Inc., a leading,provider ... announced,the completion of a $10 million Series B ... Ampersand Ventures, Adams Street,Partners and Tang Capital Management ... wealth of expertise in medical imaging and clinical,research, ...
... HUBBARD, Ohio, Nov. 28 NanoLogix, Inc. ... that the company has,submitted international patent applications ... China, India, Brazil, and the,EU (European Union). ... anticipated,global roll-out of the company,s BioNanoChannel(TM) rapid,bacteria/microorganism ...
... /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. (OTC Bulletin ... industry engaged in the development, manufacture and,distribution ... care products in China, today announced that ... Asia institutional investor conference on,December 5, 2007 ...
... Patient Implanted in San Antonio, TX -, ORANGEBURG, ... began patient enrollment in a national diabetes clinical,trial of ... with type 2 diabetes who are overweight. The study ... United States., The 300-patient trial will evaluate the ...
Cached Medicine News:Health News:The HealthCentral Network Adds Skin Care Site to Its Web Properties 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 3Health News:NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology 2Health News:China Yingxia to Present at the ICR XChange Asia Institutional Investor Conference 2Health News:MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 2
(Date:8/1/2014)... 1, 2014 In the latest call for ... dysfunction, more than 60 doctors and leading medical experts ... questioning the Food and Drug Administration,s (FDA) decision to ... of male sexual dysfunction compared with ZERO for women,s ... act for women by approving the first-ever drug to ...
(Date:8/1/2014)... 2014 In the latest call for gender ... more than 60 doctors and leading medical experts from ... the Food and Drug Administration,s (FDA) decision to approve ... male sexual dysfunction compared with ZERO for women,s most ... for women by approving the first-ever drug to treat ...
(Date:8/1/2014)... Aspire Technology Partners (Aspire) announced today that it ... This designation recognizes Aspire for delivering outstanding customer service to ... . "Achieving exceptional results for our customers is ... President and CEO of Aspire. "We are pleased Cisco has ... award and are proud to be part of the Cisco ...
Breaking Medicine Technology:60+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2
... May 3, 2012 /PRNewswire-Asia/ -- Johnson & ... has acquired Guangzhou Bioseal Biotechnology Co., Ltd. ... in the design, development and commercialization of ... bleeding during surgery. The acquisition was completed ...
... Cochlear Americas , the world,s leading implantable hearing ... smartphone support application for Nucleus® Cochlear Implant recipients. ... App as part of Cochlear,s mobile support initiative, ... and wherever they need it. (Photo: ...
Cached Medicine Technology:Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd. 2Cochlear™ Americas Adds the Nucleus® Support App to its Mobile Service Offerings 2
POLYSORB™ sutures are composed of LACTOMER™ glycolide/lactide copolymer which is a synthetic polyester composed of glycolide and lactide (derived from glycolic and lactic acids)....
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO SLIDE™ single use knot pusher with 12 units per box....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: